Trial reportDrug design, development and therapy2025
Intranasal Dexmedetomidine with Propofol Provides Superior Sedation for Pediatric Contrast-Enhanced CT: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective and safe sedation with rapid recovery remains a critical unmet need for pediatric patients undergoing contrast-enhanced computed tomography (contrast-enhanced CT). We compared the efficacy of intranasal dexmedetomidine (DEX) combined with intravenous propofol (D-P) versus DEX with buccal midazolam (D-M) for sedation during pediatric contrast-enhanced CT. Methods: In this single-center, prospective, randomized controlled trial, 110 children (6 months-6 years, ASA I/II) were allocated to D-M (2 μg/kg intranasal DEX + 0.2 mg/kg buccal midazolam) or D-P (2 μg/kg intranasal DEX + 1 mg/kg intravenous propofol). Primary outcome was one-time success rate (completed contrast-enhanced CT without additional sedation). Secondary outcomes included onset time, recovery metrics (Ramsay Sedation Scale [RSS] at 30 minutes, time to oral intake), and adverse events. Analyses followed full-analysis-set (FAS) and per-protocol-set (PPS) principles (ChiCTR2300067469). Results: The D-P group demonstrated superior one-time success rates in both FAS (96.4% vs 74.5%; OR 9.05, 95% CI 1.95-42.05, Conclusion: Intranasal dexmedetomidine combined with propofol significantly improves sedation success, accelerates recovery, and reduces procedural delays in pediatric contrast-enhanced CT compared to midazolam, offering a clinically advantageous regimen for short-duration imaging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.